
    
      Subjects will be 1:1:1 randomly assigned to receive

        -  SHR-1210 200mg, IV, Q2W and Apatinib 375mg, PO, QD, or

        -  SHR-1210 200mg, IV, Q2W and Apatinib 375mg, PO, QD（5 Days on, 2 Days off）, or

        -  SHR-1210 200mg, IV, Q2W and Apatinib 375mg, PO, QD（7 Days on, 7 Days off） treatment
           until disease progression, unacceptable toxicity, or death.
    
  